Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Diabete Type 2
Phase PHASE3
Enrollment 390
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

This randomized controlled trial (RCT) will determine if access to a voucher for healthy foods reduces blood sugar levels among people living on a low income who have type 2 diabetes or elevated blood sugar.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Behavioral: Food voucher — A voucher of that can be redeemed for food at grocery stores.

Primary Outcomes

  • Hemoglobin A1c (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-03-21
Completion: 2027-04-01
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 390 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Unity Health Toronto
Contact Information
Study Contact:
Nav Persaud
416-864-6060
nav.persaud@utoronto.ca
Nav Persaud, MD
nav.persaud@utoronto.ca
St Michael's Hospital Academic Family Health Team
Interventions
  • Behavioral: Food voucher — A voucher of that can be redeemed for food at grocery stores.
Study Locations (1 sites)
St Michael's Hospital Academic Family Health Team, Toronto, Canada
Eligibility Criteria
Inclusion Criteria: * hemoglobin A1c 6.0 to 11.0 * report food insecurity or financial insecurity Exclusion Criteria: * live with a current study participant * life expectancy \< 6 months * multiple life-threatening allergies to common foods * require total parenteral nutrion * blood dyscrasia that interferes with hemoglobin A1c interpretation * hemoglobin A1c \>11
Conditions Overweight/Obesity, Metabolic Dysfunctio...
Phase PHASE1
Enrollment 32
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the pharmacokinetic effects of a single dose of HRS-4729 injection in participants with mild, moderate, and severe renal impairment, with 8 participants enrolled in each renal impairment group and 8 healthy participants.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: HRS-4729 — Each subject will receive a single subcutaneous dose of HRS-4729 injection solution.

Primary Outcomes

  • Cmax (assessed up to approximately 4 weeks post-dose;)
  • AUC0-t (assessed up to approximately 4 weeks post-dose)
  • AUC0-inf. (assessed up to approximately 4 weeks post-dose)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-09-09
Completion: 2027-03-15
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: true
Enrollment: 32 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Contact Information
Study Contact:
Ziwei Du
0518-82342973
ziwei.du.zd9@hengrui.com
Mengchang Yang
Sichuan Provincial People's Hospital
Interventions
  • Drug: HRS-4729 — Each subject will receive a single subcutaneous dose of HRS-4729 injection solution.
Study Locations (1 sites)
Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072 China
Eligibility Criteria
Inclusion Criteria: 1. Provide written informed consent prior to any study-related procedures, and have a full understanding of the study content, procedures, and potential adverse events. 2. Be aged 18 to 65 years (inclusive), of either sex. 3. Have a body mass index (BMI) between 19 and 40 kg/m² (inclusive). 4. Glomerular filtration rate (absolute eGFR) must meet the relevant requirements and criteria specified in the protocol. 5. Have stable renal function. 6. Women of childbearing potential must have been using reliable contraception and have a negative serum pregnancy test at baseline, and must be willing to use highly effective contraceptive measures from the time of signing informed consent until 2 months after the last dose of study drug. Male Participants must be willing not to plan to father a child during the trial and until 2 months after the last dose, and voluntarily take effective contraceptive measures, or have undergone surgical sterilization. 7. Healthy participants: demographic means at screening must match those of the renal impairment groups as follows: Body weight matched within ±10 kg of the group mean; Age matched within ±10 years of the group mean; Sex ratio matched within ±1 subject. 8.For participants in the renal impairment groups: Participants must have a diagnosis of chronic (\>3 months) and stable (no acute deterioration of renal function within 1 month prior to screening) renal impairment. Exclusion Criteria: 1. Have a history of significant abnormal gastric emptying, severe gastrointestinal disease, or gastrointestinal surgery (except gastrointestinal polypectomy), as assessed by the investigator to be unsuitable for participation. 2. Have a history or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2), or a history of pancreatitis or symptomatic cholelithiasis. 3. Have a history of malignancy in any organ system within the past 5 years, regardless of evidence of local recurrence or metastasis, with the exception of cured localized basal cell carcinoma of the skin, carcinoma in situ of the cervix, and carcinoma in situ of the prostate. 4. Have undergone any surgery within 6 months prior to dosing, or plan to undergo surgery during the study period (excluding gastrointestinal polypectomy). 5. Have participated in any clinical trial of a drug or medical device within 3 months prior to dosing. Participation in a clinical trial is defined as having signed informed consent and having used the investigational product (including placebo) or investigational medical device; or are still within the follow-up period of another clinical study or within 5 half-lives of the investigational drug (whichever is longer). 6. Have had blood loss or blood donation of ≥400 mL within 3 months prior to dosing, or ≥200 mL within 1 month prior to dosing, or have received a blood transfusion within 3 months prior to dosing. 7. Have a known history of severe drug allergy or drug hypersensitivity; 8. Test positive for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCVAb), human immunodeficiency virus (HIV) antibody, or positive for rapid plasma reagin (RPR) test or toluidine red unheated serum test (TRUST) for syphilis. 9. Have a history of drug abuse or substance abuse within 1 year prior to dosing, or test positive on urine multi-drug screening. 10. Are habitual smokers or drinkers and are unable to abstain during the trial; or have a positive alcohol breath test. 11. Have used receptor agonists or inhibitors related to the investigational drug within 2 months prior to screening; Participants who discontinued the above agents due to intolerance more than 2 months prior to screening should also be excluded. 12. Are pregnant or lactating women at the time of screening and baseline visits. 13. Have consumed foods or beverages containing methylxanthines (e.g., tea, coffee, cola, chocolate, energy drinks) or alcohol within 48 hours prior to the first dose of study drug; or have engaged in strenuous exercise within that period. 14. Have a history of needle phobia, syncope with blood or needles, difficulty in blood collection, or intolerance to venipuncture. 15. Have special dietary habits that, in the investigator's opinion, make them unsuitable for participation, or are unable to comply with the dietary requirements during the trial. 16. Have any other condition that, in the investigator's opinion, makes the subject unsuitable for the study, or withdraw voluntarily for personal reasons. 17. For healthy participants: 1)At screening, have systolic blood pressure \<90 mmHg or ≥140 mmHg, diastolic blood pressure \<50 mmHg or ≥90 mmHg, or heart rate \<50 bpm or \>100 bpm. 2)Have a history of significant diseases involving the cardiovascular, hepatic, renal, digestive, psychiatric/neurological, endocrine, respiratory, hematological, or immune systems prior to screening. Have used any medication (including over-the-counter drugs, herbal medicines, and dietary supplements) that, in the investigator's judgment, may affect the study results, within 14 days or 5 half-lives (whichever is longer) prior to dosing. 3)Have clinically significant abnormalities in physical examination, vital signs, laboratory tests (hematology, biochemistry, urinalysis, coagulation, etc.), or 12-lead electrocardiogram (including QTcF) at screening. 18.For participants with renal impairment: 1. Have poorly controlled blood pressure despite pharmacological intervention at screening: systolic blood pressure \<90 mmHg or ≥160 mmHg, diastolic blood pressure \<50 mmHg or ≥100 mmHg, or heart rate \<50 bpm or \>100 bpm. 2. Have obstructive uropathy (e.g., urinary stones, urinary obstruction due to abdominal space-occupying lesions) and/or diseases that may cause renal damage (e.g., renal artery stenosis, acute drug-induced injury, severe infection, hypovolemia). 3. Have a history of severe disease involving the cardiovascular (except for well-controlled hypertension within the past month), respiratory, hepatic, gastrointestinal, endocrine (except for hyperlipidemia, hyperuricemia, and diabetes with stable blood glucose within the past month), hematological, or psychiatric/neurological systems within 1 year prior to screening, as assessed by the investigator to be unsuitable for participation; or have a prior diagnosis of decompensated heart failure (NYHA Class III or IV). 4. Have undergone renal transplantation. 5. Have not been on a stable regimen of therapeutic medications for their renal disease and/or other comorbidities for at least 1 month prior to screening, or have had any new medication added within 1 month prior to screening (excluding temporary or intermittent medications, such as erythropoietin administered once monthly or as-needed diuretics); or have received any drug known to affect renal tubular secretion of creatinine (e.g., cimetidine, trimethoprim, or cibenzoline) within 14 days or 5 half-lives (whichever is longer) prior to dosing. 6. Have any of the following abnormalities in laboratory tests (hematology, biochemistry, urinalysis, coagulation, etc.) or 12-lead ECG at screening: 1. Hemoglobin \<85 g/L; 2. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3× upper limit of normal (ULN), and total bilirubin (TBIL) ≥1.5× ULN; 3. Fasting triglycerides (TG) \>5.64 mmol/L (500 mg/dL); 4. Clinically significant abnormalities in serum amylase or lipase; 5. QTcF (Fridericia-corrected) \>450 msec in males or \>470 msec in females; 6. Any other laboratory abnormality that, in the investigator's opinion, may affect subject safety.
Conditions Type II Diabetes Mellitus
Phase PHASE2
Enrollment 240
Locations 48 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

This study is testing whether a new medication called CX11 works and is safe for participants with type 2 diabetes who have not reached good blood sugar control while taking a steady dose of metformin, with or without a steady dose of an SGLT2 inhibitor, for at least 90 days. The study is being done at multiple medical centers. Participants are assigned by chance (randomized) to different groups, and neither the participants nor the study staff know which group they're in (double-blind). The groups are compared side by side (parallel), and some participants will receive inactive pills (placebo) to help measure the true effect of the study drug. After screening, participants will be randomly placed into one of six groups, with equal chances of being in any group. Each group will receive a different dose of CX11 or a placebo. Treatment will last 24 weeks. After that, all participants will have a 2-week follow-up period to check on safety.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: CX11 — CX11 tablets administered orally once daily (QD)
  • Other: Placebo — Matching placebo tablets administered orally once daily (QD)

Primary Outcomes

  • Change in Glycosylated hemoglobin, Type A1C (HbA1c) from baseline (At Week 24)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-02-06
Completion: 2027-04-30
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 240 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Corxel Pharmaceuticals
Contact Information
Study Contact:
Study Coordinator
201-268-3723
information.center@corxelbio.com
Interventions
  • Drug: CX11 — CX11 tablets administered orally once daily (QD)
  • Other: Placebo — Matching placebo tablets administered orally once daily (QD)
Study Locations (48 sites)
Central Research Associates - Flourish - PPDS, Birmingham, Alabama 35205-1605 United States
AES - DRS - Synexus Clinical Research US, Inc. - Birmingham, Birmingham, Alabama 35211-1320 United States
AES - DRS - Optimal Research Alabama - Huntsville, Huntsville, Alabama 35802-2569 United States
Core Healthcare Group, Cerritos, California 90703 United States
Ark Clinical Research - Long Beach, Long Beach, California 90815-2521 United States
Flourish Research - Walnut Creek - PPDS, Walnut Creek, California 94598-3343 United States
AES - DRS - Optimal Research Florida - Melbourne, Melbourne, Florida 32934-8172 United States
Tampa General Hospital, Tampa, Florida 33606-3571 United States
Conquest Research LLC - Winter Park, Winter Park, Florida 32789-1857 United States
Privia Medical Group Georgia, LLC - Albany - Javara - PPDS, Albany, Georgia 31707-0205 United States
Eligibility Criteria
Inclusion Criteria Participants who meet all of the following criteria will be eligible to participate in this study: * Adults aged 18 to 75. * Diagnosis of type 2 diabetes for at least 6 months. * HbA1c between 7.0% and 10.5%. * Body mass index (BMI) between 23 and 50 kg/m². * Body weight stable for the past 3 months before joining. * Stable dose of metformin (≥1000 mg/day), with or without SGLT2i, for ≥3 months. * Women of childbearing potential (WOCBP): highly effective contraception ≥6 months prior to screening, throughout study, and 90 days post-last dose; negative pregnancy test within 24 hrs of first dose; no intent to donate sperm/ova * Agrees to avoid grapefruit/grapefruit products Exclusion Criteria Participants who meet any of the following criteria will be excluded from this study: * Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or systemic corticosteroids). * Type 1 diabetes or a history of diabetic ketoacidosis. * Use of any GLP-1 receptor agonist within the past 6 months, or any prior exposure to CX11. * Use of insulin to control blood sugar within the past 12 months. * More than one episode of severe low blood sugar, with awareness of hypoglycemia symptoms. * Cardiovascular or cerebrovascular conditions within the past 6 months: * Heart attack, coronary angioplasty, or bypass surgery (diagnostic angiography allowed). * Valvular heart disease or prior heart valve repair surgery. * Unstable angina. * Transient ischemic attack (TIA) or stroke. * Decompensated heart failure (NYHA Class III or IV). * ECG abnormalities indicating significant safety risk, such as supraventricular tachycardia, torsades de pointes, second- or third-degree AV block, myocardial infarction, QTcF \> 450 ms in males or \> 470 ms in females, PR interval \> 220 ms. * Poorly controlled hypertension at screening: systolic ≥ 180 mmHg or diastolic ≥ 100 mmHg. * Pancreatic or gallbladder conditions: * Acute or chronic pancreatitis. * Symptomatic gallbladder disease (previous cholecystectomy is allowed). * Pancreatic injury or risk factors that increase pancreatitis risk. * Thyroid conditions: * Poorly controlled abnormal thyroid function on a stable dose before screening. * Clinically significant abnormal thyroid test results at screening. * Personal or first-degree family history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) type 2A or 2B. * Cancer history: * Malignancy within the past 5 years, regardless of recurrence or metastasis. Exceptions: localized basal cell skin cancer, low-risk prostate cancer, cervical carcinoma in situ, or high-grade prostatic intraepithelial neoplasia. * Gastrointestinal conditions or treatments that may affect drug absorption: * Abnormal gastric emptying (e.g., gastric outlet obstruction). * Severe chronic gastrointestinal disease, including active ulcer within 6 months. * Crohn's disease, ulcerative colitis, or other inflammatory bowel diseases. * Prior gastrointestinal surgery (except polypectomy and appendectomy). * Long-term use of drugs that directly affect gastrointestinal motility (e.g., mosapride, cisapride). * Liver disease: * Active liver disease other than nonalcoholic fatty liver. * Chronic active hepatitis B or C. * Primary biliary cirrhosis. * Eye disease: * Uncontrolled or potentially unstable diabetic retinopathy or maculopathy. * Abnormal lab results at screening: * eGFR \< 60 mL/min/1.73 m² (CKD-EPI). * ALT or AST \> 2.5 × upper limit of normal (ULN). * Total bilirubin \> 1.5 × ULN (except known Gilbert's syndrome). * Serum amylase or lipase \> 1.5 × ULN. * Fasting triglycerides \> 5.7 mmol/L. * TSH \> 1.5 × ULN or \< 1.0 × LLN. * Calcitonin ≥ 20 ng/L. * Hemoglobin \< 110 g/L (male) or \< 100 g/L (female).
Conditions Type 1 Diabetes, New Onset
Phase PHASE1, PHASE2
Enrollment 120
Locations 11 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

This multi-center randomized controlled trial will assess the safety and efficacy of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons aged 9 to \<21 with recent-onset stage 3 T1D.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Anti-thymocyte globulin (ATG) — ATG (brand name Thymoglobulin) a polyclonal T cell antibody preparation. The first dose (0.5 mg/kg) will be infused on day 0, during a period of 6 hours. The second dose (2 mg/kg) will be given on day 1, over a period of 4 to 6 hours.
  • Drug: verapamil extended-release capsule — Daily oral (pill) administration at 60, 120, 240 or 360 mg based on weight and ECG findings.
  • Drug: Adalimumab — 40 mg administered subcutaneously every other week beginning 6 weeks after the last dose of ATG until the 156-week visit.

Primary Outcomes

  • Stimulated C-peptide AUC (Week 104)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2026-03-10
Completion: 2031-04-15
Eligibility
Age: 9 Years – 20 Years
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: City of Hope Medical Center
Collaborators: Jaeb Center for Health Research
Principal Investigators:
  • Alberto Pugliese, MD (STUDY_CHAIR) - City of Hope Medical Center
Contact Information
Study Contact:
Robert Henderson, MS
813-975-8690
rhenderson@jaeb.org
Angela Martinez
3108250867
angelamartinez@mednet.ucla.edu
UCLA
Christina Reh, MD
UCLA
Interventions
  • Drug: Anti-thymocyte globulin (ATG) — ATG (brand name Thymoglobulin) a polyclonal T cell antibody preparation. The first dose (0.5 mg/kg) will be infused on day 0, during a period of 6 hours. The second dose (2 mg/kg) will be given on day 1, over a period of 4 to 6 hours.
  • Drug: verapamil extended-release capsule — Daily oral (pill) administration at 60, 120, 240 or 360 mg based on weight and ECG findings.
  • Drug: Adalimumab — 40 mg administered subcutaneously every other week beginning 6 weeks after the last dose of ATG until the 156-week visit.
Study Locations (11 sites)
UCLA, Los Angeles, California 90095 United States
UCSF, San Francisco, California 94143 United States
Yale University, New Haven, Connecticut 06511 United States
University of Florida, Gainesville, Florida 32610 United States
University of Miami, Miami, Florida 33136 United States
Indiana University, Indianapolis, Indiana 46202 United States
University of Minnesota, Minneapolis, Minnesota 55455 United States
University of Buffalo, Buffalo, New York 14203 United States
University of Pittsburgh, Pittsburgh, Pennsylvania 15224 United States
Baylor College of Medicine, Houston, Texas 77030 United States
Eligibility Criteria
Key Inclusion Criteria: 1. Recent-onset stage 3 T1D diagnosed by standard ADA criteria, with the ability to be randomized within 6 months from the date of T1D diagnosis and within 37 days of Screening Visit. 2. At least one positive T1D auto-antibody. * If clearly positive (≥20% above local lab's ULN) at screening, repeat antibody testing for central lab is not required. * Insulin auto-antibodies are only considered if exogenous insulin use is \<10 days when blood is drawn. 3. Must have stimulated C-peptide levels ≥0.2 pmol/mL (≥0.6 ng/mL) measured during MMTT conducted prior to randomization. 4. Age 9 to \<21 years at the time of randomization. 5. Body weight \>30kg. 6. BMI \<95th percentile for age and gender. 7. Willing to comply with intensive diabetes management. 8. Female participants with childbearing potential are not currently pregnant, are willing to avoid pregnancy and breastfeeding, and to undergo pregnancy testing prior to MMTTs for the duration of the study. a. Women of childbearing potential (WOCBP) must use an acceptable form of birth control. Acceptable forms include oral/injection contraceptives, transdermal contraceptives, diaphragm, intrauterine devices, condoms with spermicide, documented surgical sterilization of either the participant or their partner or abstinence. 9. Male participants with potential to father children must be willing to use abstinence or adequate contraceptive methods for the duration of the study. a. Males must agree to be sexually abstinent or use a condom and agree not to donate sperm for the treatment period and for a minimum of 1 spermatogenesis cycle (90 days after last dose of study drug) after last treatment. 10. Willing to provide informed consent and child assent as applicable. 11. Willing to provide their primary endocrinologist's contact information and have their primary endocrinologist notified of their participation 12. Sufficient cognitive ability, per investigator judgment, to provide informed consent for study participation on an IRB approved consent form. 13. Able to read and understand English or Spanish (both participant and legally authorized representative, if applicable). 14. Must be fully vaccinated for age. 15. Must have been vaccinated for flu (if currently in flu season). 16. Must be willing to not receive live vaccines throughout the treatment period. 17. Must be willing to not use any non-insulin glucose-lowering agents such as GLP-1 agonists (including for weight loss indication), symlin, DPP-4 inhibitors, SGLT-2 inhibitors, biguanides, sulfonylureas) for the duration of study treatment. Participants are required to go off these drugs at least 30 days prior to screening. Key Exclusion Criteria: 1. Prior treatment with ATG or known allergy to ATG or rabbit-derived products. 2. Local lab draw at screening: 1. Immunodeficient or have clinically significant chronic lymphopenia: Leukopenia (\<3,000 leukocytes /μL), neutropenia (\<1,500 neutrophils/μL), lymphopenia (\<800 lymphocytes/μL). 2. Thrombocytopenia (\<100,000 platelets/μL) or anemia (hemoglobin \< 10g/dL). 3. Leukocytosis (\>14,000/μL) 3. Infections: 1. Ongoing infection or had recently had a major infection requiring hospitalization or intravenous antibiotics.within 30 days prior to randomization. 2. Have active signs or symptoms of acute infection at the time of randomization. 3. Have evidence of prior or current tuberculosis infection as assessed interferon gamma release assay (QuantiFERON-TB Gold), or a positive test for latent tuberculosis. 4. Have evidence of current or past HIV or Hepatitis B or current Hepatitis C infection. 5. History of serious bacterial, viral, fungal, or other opportunistic infections. 4. Have active signs or symptoms of CMV or EBV compatible illness lasting more than 7 days within 30 days of randomization. 5. Have positive CMV and/or EBV PCR test within 30 days prior to randomization. 6. Have positive COVID-19 self-antigen test within 3 days of randomization. 7. History of underlying cardiac disease (ex. left ventricular dysfunction, hypertrophic cardiomyopathy), certain arrhythmias (e.g. AV block, accessory pathway such as Wolff- Parkinson-White or Lown-Ganong-Levine syndromes) or abnormal ECG (unless cleared by cardiology). 8. Blood pressure (either systolic or diastolic) \<5th percentile for age, gender, and height on two out of three measurements. 9. Pulse \<2.5th percentile for age and gender on two out of three measurements. 10. History of vasovagal syncopal episodes related to hypotension. 11. History of malignancies other than of skin. 12. Use of medications likely to interfere with study results: 1. Any immunomodulators, including systemic steroids or participation in prior research study in which a potential participant received an immunomodulatory agent (may participate if received placebo only). 2. Current or previous use of Teplizumab, Adalimumab, or Verapamil. 3. Ongoing use of medications known to influence glycemia or glucose tolerance. Only topical steroids are allowed. 13. Need to use of any of the following medications during the study: beta blocker, seizure medication (carbamazepine, phenobarbital, phenytoin), other antihypertensive medications, HMG-CoA reductase inhibitors, lithium, theophylline, clonidine. 14. Receipt of live vaccine (e.g., varicella, measles, mumps, rubella, cold-attenuated intranasal influenza vaccine, bacillus Calmette-Guerin, and smallpox) within the 90 days before randomization. 15. Any known hypersensitivity reaction to any of the study medications or their components. 16. Unable to swallow pills (tested with an inert imitation tablet in clinic at screening). 17. History of significant allergy (e.g., anaphylaxis) to milk or soy proteins in the Boost drink required for study MMTT testing. 18. Current use of hydroxyurea or unable to avoid hydroxyurea use during the study (interferes with accuracy of Dexcom sensor). 19. Established history of allergy or severe reaction to adhesive or tape that must be used in the study. 20. Participation in another treatment research study that involves diabetes care or immune modulation, unless the participant is able to confirm that they were in the placebo arm. 21. Presence of a medical condition or use of a medication that, in the judgment of the investigator, clinical protocol chair, or medical monitor, could compromise the results of the study or the safety of the participant. Conditions to be considered by the investigator may include the following: 1. Alcohol or drug abuse 2. Untreated or inadequately treated mental illness 3. Liver disease or LFTs \>2x ULN. 4. Renal disease or creatinine greater than 1.5x ULN. 5. Other autoimmune diseases except for stable and treated hypothyroidism Graves' disease, or celiac disease (e.g., symptom-free on a gluten free diet). 6. Nervous system disorder including but not limited to Guillain-Barre Syndrome, multiple sclerosis, progressive multifocal leukoencephalopathy. 7. History of multiple abdominal surgeries and/or at increased risk for bowel obstruction. 22. Any clinical or laboratory conditions that the investigator feels would interfere with the study or participant safety (e.g., increased risk to pre-existing disease). Any lab abnormality believed to be transient may be repeated at the discretion of the site PI. If repeat value does not preclude participation, and potential participant would otherwise qualify for the study, then may proceed with enrollment per investigator discretion. \-
Conditions Type 2 Diabetes
Phase PHASE2
Enrollment 216
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

This study is a multicenter, randomized, double-blind (with open-label dose levels and active comparator), parallel-group, placebo- and active-controlled Phase 2 clinical trial aimed at evaluating the efficacy, safety, immunogenicity, and pharmacokinetic (PK) characteristics of HDM1005 in subjects with Type 2 Diabetes Mellitus (T2DM) who have inadequate glycemic control after diet/exercise or metformin therapy. A total of 216 subjects will be enrolled. All subjects will be stratified by baseline HbA1c levels (≤8.5% or \>8.5%) and prior metformin use, then randomized 1:1:1:1:1:1 to: Group 1 (HDM1005 0.5 mg), Group 2 (HDM1005 1.0 mg), Group 3 (HDM1005 2.0 mg), Group 4 (HDM1005 3.0 mg), Group 5 (Placebo), and Group 6 (open-lable dulaglutide 1.5 mg, active comparator), with 36 subjects in each treatment group. Within each dose cohort (0.5/1.0/2.0/3.0mg), there will be \~45 total subjects (36 HDM1005 + 9 placebo). The 1.0mg, 2.0mg, and 3.0mg cohorts will implement dose titration. The study consists of: 2-week screening, 20-week treatment, and 4-week safety follow-up. The end-of-study visit will be conducted 28 days after the last administration cycle.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: HDM1005 1 — administered SC, QW, 20 weeks
  • Drug: HDM1005 2 — administered SC, QW, 20 weeks
  • Drug: HDM1005 3 — administered SC, QW, 20 weeks
  • Drug: HDM1005 4 — administered SC, QW, 20 weeks
  • Drug: Placebo — administered SC, QW, 20 weeks
  • Drug: Dulaglutide 1.5 MG — administered SC, QW, 20 weeks

Primary Outcomes

  • Change from baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 20)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-04-30
Completion: 2026-02-28
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 216 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Contact Information
Study Contact:
Lepeng Li
+86 18301051549
lilepeng@eastchinapharm.com
Interventions
  • Drug: HDM1005 1 — administered SC, QW, 20 weeks
  • Drug: HDM1005 2 — administered SC, QW, 20 weeks
  • Drug: HDM1005 3 — administered SC, QW, 20 weeks
  • Drug: HDM1005 4 — administered SC, QW, 20 weeks
  • Drug: Placebo — administered SC, QW, 20 weeks
Study Locations (1 sites)
Peking University People's Hospital, Beijing, Beijing Municipality China
Eligibility Criteria
Inclusion Criteria: * Confirmed as Type 2 Diabetes Mellitus (T2DM) for at least 24 weeks; * Hemoglobin A1c (HbA1c) ≥7.5% and ≤10.5% * Body Mass Index (BMI within the range of 22.5 \~ 40.0 kg/m2 Exclusion Criteria: * Other types of diabetes besides T2DM * Acute complications of diabetes (such as diabetic ketoacidosis, diabetic lactic acidosis, or hyperosmolar non-ketotic coma) occurred within 24 weeks prior to signing the Informed Consent Form (ICF) * History of a level 3 hypoglycemic episode or a history of asymptomatic hyp oglycemic episodes within 24 weeks prior to signing the ICF * History or family history of medullary thyroid carcinoma (MTC), thyroid C-cell hyperplasia, or multiple endocrine neoplasia type 2 (MEN2) * History of acute or chronic pancreatitis; or presence of risk factors for pancreatitis; or history of symptomatic gallbladder disease within 24 weeks prior to signing the ICF * Investigator determines that the subject has a condition or disease affecting gastric emptying or gastrointestinal nutrient absorption, such as weight-loss surgery or other gastric resections, irritable bowel syndrome, dyspepsia, or gastroparesis * Use of antidiabetic medications within 12 weeks prior to signing the ICF * Hemoglobin (Hb) \<100 g/L (female) or \<110 g/L (male) * FPG ≥13.9 mmol/L * Aspartate aminotransferase (AST) \>2.5× upper limit of normal (ULN) and/or alanine aminotransferase (ALT) \>2.5× ULN * Total bilirubin \>1.5× ULN * Fasting triglyceride (TG) \>5.6 mmol/L (500 mg/dL)
Conditions Obesity, Childhood, Type 2 Diabetes Mell...
Phase Not Applicable
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

The investigators will measure blood levels of 1,5-anhydroglucitol in obese children with or without type 2 diabetes and correlate them with parameters related to functional beta-cell mass and glucose metabolism. The values will be compared to those obtained in healthy volunteers. The aim of the study is to test the validity of 1,5-anhydroglucitol as a novel biomarker of beta-cell mass and function in children with obesity with or without type 2 diabetes.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Other: Measurement of biomarker — Measurement of blood levels of 1,5-anhydroglucitol

Primary Outcomes

  • Correlation of 1,5-anhydroglucitol levels in obese children with indirect markers of beta-cell function and mass and with metabolic control (First oral glucose tolerance test)
  • Correlation of 1,5-anhydroglucitol levels in obese children with indirect markers of beta-cell function and mass and with metabolic control (Second oral glucose tolerance test, 2 years after the first)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-11-22
Completion: 2028-12-31
Eligibility
Age: 12 Years – 16 Years
Sex: ALL
Volunteers: Not specified
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Philippe Klee, MD-PhD
Collaborators: University of Geneva, Switzerland
Contact Information
Study Contact:
Philippe Klee
+41 79 55 33 476
philippe.klee@unige.ch
Pierre Maechler
pierre.maechler@unige.ch
Philippe Klee, MD-PhD
+41 79 55 33 476
philippe.klee@hcuge.ch
University Hospital of Geneva
Interventions
  • Other: Measurement of biomarker — Measurement of blood levels of 1,5-anhydroglucitol
Study Locations (1 sites)
University Hospital of Geneva, Geneva, Canton of Geneva 1211 Switzerland
Eligibility Criteria
Inclusion Criteria: * Children aged 12 to 16 years * Obesity. Defined as a body-mass index above the 97th percentile. * Ability to give informed consent as documented by signature Exclusion Criteria: * Patients with diabetes mellitus and positive autoantibodies against islets, insulin, islet antigen 2, glutamic acid decarboxylase or Zinc transporter 8. * Patients with known liver disease (other than NAFLD) * Patients treated with an oral antidiabetic drug, glucagon-like peptide-1 analogues or insulin at the time of or less than 2 weeks prior to inclusion. * Patients treated with a drug known to affect liver function
Conditions Type 2 Diabetes Mellitus (T2DM), Malnutr...
Phase Not Applicable
Enrollment 334
Locations 12 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

The objective of this observational study is to characterize the patient profile and nutritional treatment patterns of individuals with type 2 diabetes (T2D) or drug-induced diabetes who present with malnutrition, or are at risk of it, and who are prescribed a diabetes-specific oral nutritional supplement (ONS) that is high in calories and protein and contains soluble fiber. Participants will complete a series of questionnaires during visits 1 and 3.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Descriptive of study population (Baseline visit (V1))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-11-20
Completion: 2026-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 334 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Outcomes'10
Collaborators: Nestlé Health Science Spain
Contact Information
Study Contact:
Mercedes Blanco Naveira, Medical Adviser. MD
+34 628 237 634
mercedes.blanco@es.nestle.com
Interventions
N/A
Study Locations (12 sites)
Hospital Universitario Marqués de Valdecilla, Santander, Cantabria 39008 Spain
Hospital Universitario Juan Ramón Jiménez, Huelva, Huelva 21005 Spain
Hospital UniversitarioDoctor Negrín, Las Palmas de Gran Canaria, Las Palmas 35010 Spain
Hospital La Princesa, Madrid, Madrid 28006 Spain
Hospital Clínico San Carlos, Madrid, Madrid 28040 Spain
Hospital Universitario La Paz, Madrid, Madrid 28046 Spain
Hospital Virgen de la Victoria, Málaga, Malaga 29010 Spain
Hospital Universitario Central de Asturias, Oviedo, Principality of Asturias 33011 Spain
Hospital Universitario Virgen del Rocío, Seville, Sevilla 41005 Spain
Hospital Universitario Virgen de la Macarena, Seville, Sevilla 41009 Spain
Eligibility Criteria
Inclusion Criteria: * Adult patients diagnosed with type 2 diabetes (T2D) or drug-induced diabetes * Patients at nutritional risk according to MUST or presenting malnutrition according to GLIM criteria. * Patients requiring a diabetes-specific oral nutritional supplement (ONS) that is high-calorie, high-protein, and contains soluble fiber in real-world clinical practice, and who have been prescribed such a supplement within the previous 7 days. * Patients able to provide informed consent and complete the study questionnaires. Exclusion Criteria: * Patients participating in other studies or clinical trials related to malnutrition, or who, in the investigator's opinion, may alter the course of the study. * Patients currently receiving or expected to receive other types of nutritional interventions involving supplements (oral or otherwise) or non-conventional feeding methods (e.g., feeding tubes). * Patients with a history of metabolic/endocrine diseases (other than diabetes) or any other condition causing liver or kidney failure, defined as ALT \> 3x ULN or eGFR \< 30 ml/min/1.73 m², and according to the investigator's judgment. * Patients expected to undergo any surgical intervention or require hospitalization due to a condition unrelated to the study during the study period. * Patients with other conditions that, in the investigator's opinion, may interfere with adherence to the intervention or with study procedures.
Conditions Type 2 Diabetes (T2DM), Obesity Type 2 D...
Phase NA
Enrollment 80
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective, open-label, randomized controlled trial involving 80 adult patients with newly diagnosed T2DM (diagnosed within the last 3 months) recruited at the Bogomolets National Medical University. Participants may be lifestyle-controlled or receiving stable non-insulin anti-diabetic medications. Participants will be randomized in a 1:1 ratio to either the Real-Time Continuous Glucose Monitoring group (CGM group) or the control group (standard Self-Monitoring of Blood Glucose \[SMBG\] using conventional glucometers). The gathered data will help determine whether the real-time visual feedback provided by CGM systems superiorly improves glycemic variability, optimizes metabolic parameters, and enhances patient adherence to lifestyle interventions and pharmacological treatment compared to conventional SMBG methods in the early stages of T2D.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Device: CGM Sibionics — A registered medical device for real-time monitoring of glucose levels in interstitial fluid.
  • Device: On-Call Extra Glucometer — Capillary glucose monitoring using fingerstick glucometer as per standard care.

Primary Outcomes

  • Changes in HbA1c level (at 3 month (end of follow-up period))
  • Changes in Fructosamine level (at 1 month (end of intervention period))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-15
Completion: 2027-03-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nazarii Kobyliak
Collaborators: COR-Medical LLC, Iridium LLC
Contact Information
Study Contact:
Nazarii Kobyliak, Professor
0442356005
nazariikobyliak@gmail.com
Bogomolets National Medical University
Ilona Rudneva, PhD Student
0442356005
ilonarudneva57@gmail.com
Bogomolets National Medical University
Nazarii Kobyliak, Professor
Bogomolets National Medical University
Interventions
  • Device: CGM Sibionics — A registered medical device for real-time monitoring of glucose levels in interstitial fluid.
  • Device: On-Call Extra Glucometer — Capillary glucose monitoring using fingerstick glucometer as per standard care.
Study Locations (3 sites)
Bogomolets National Medical University, Kyiv, 01601 Ukraine
Bogomoletz Institute of Physiology, Kyiv, 01601 Ukraine
University Hospital of Bogomolets National Medical University, Kyiv, 01601 Ukraine
Eligibility Criteria
Inclusion Criteria: * Age of 18 years and older. * Newly diagnosed Type 2 Diabetes Mellitus according to ADA (American Diabetes Association) criteria (Fasting Plasma Glucose ≥ 7.0 mmol/L, or 2-hour Post-Prandial Glucose ≥ 11.1 mmol/L during OGTT, or HbA1c ≥6.5%). * Time since the initial diagnosis of T2D must not exceed 3 months ( less 90 days) at the time of screening. * HbA1c level between 6.5% and 9.5% (inclusive) at screening. * Patients may be lifestyle-controlled or receiving any stable non-insulin anti-diabetic therapy (including Metformin, SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, or Sulfonylureas) as monotherapy or combination therapy. * Ability to provide written informed consent and willingness to adhere to the study protocol and follow-up schedule. Exclusion Criteria: * Diagnosis or suspicion of Type 1 Diabetes, Latent Autoimmune Diabetes in Adults (LADA) (e.g., positive anti-GAD antibodies if tested), or secondary types of diabetes (e.g., pancreatic or drug-induced). * Any prior or current use of insulin therapy. * Severe microvascular or macrovascular complications (proliferative retinopathy, severe diabetic nephropathy with eGFR \< 45 mL/min/1.73m², diabetic foot ulcers, severe peripheral neuropathy). * Endocrine disorders (e.g., Itsenko-Cushing syndrome, acromegaly) that affect glycemia. * History of myocardial infarction, stroke, unstable angina, coronary artery bypass graft (CABG), or percutaneous coronary intervention (PCI) within the past 6 months. * Active malignancy, decompensated heart failure (NYHA Class III or IV), or chronic infectious diseases. * Pregnant or breastfeeding women, or women of childbearing potential not using highly effective contraception. * Has evidence of current abuse of drugs or alcohol or a history of abuse that, in the investigator's opinion, would cause the individual to be noncompliant. * Participation in another clinical study within the last 3 months.
Conditions Diabete Type 2
Phase PHASE1, PHASE2
Enrollment 24
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is an approved and well-established therapy for type 2 diabetes mellitus (T2DM), providing both robust glycemic control and weight reduction. Semaglutide Depot, is a long-acting formulation of semaglutide, designed for once every four weeks administration, intended to reduce treatment burden, and improve adherence supporting sustained glycemic control over time. This Phase I/Ila dose escalation study design to evaluate the safety, tolerability, pharmacokinetics and efficacy of Semaglutide Depot in adults with T2DM.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: SG Depot 2 mg — 2 mg administered subcutaneously (s.c., under the skin) once every 4 weeks
  • Drug: SG Depot 4 mg — 4 mg administered subcutaneously (s.c., under the skin) once every 4 weeks
  • Drug: SG Depot 6 mg — 6 mg administered subcutaneously (s.c., under the skin) once every 4 weeks
  • Drug: SG Depot 8 mg — 8 mg administered subcutaneously (s.c., under the skin) once every 4 weeks

Primary Outcomes

  • The rate of treatment-associated adverse events (AEs) (Through study completion, up to 28 weeks for each subject)
  • Plasma concentration of semaglutide (Through study completion, up to 28 weeks for each subject)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2026-08-09
Completion: 2028-06
Eligibility
Age: 18 Years – 64 Years
Sex: ALL
Volunteers: false
Enrollment: 24 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mapi Pharma Ltd.
Contact Information
Study Contact:
Roy Eldor, Professor
972-36974243
roye@tlvmc.gov.il
Interventions
  • Drug: SG Depot 2 mg — 2 mg administered subcutaneously (s.c., under the skin) once every 4 weeks
  • Drug: SG Depot 4 mg — 4 mg administered subcutaneously (s.c., under the skin) once every 4 weeks
  • Drug: SG Depot 6 mg — 6 mg administered subcutaneously (s.c., under the skin) once every 4 weeks
  • Drug: SG Depot 8 mg — 8 mg administered subcutaneously (s.c., under the skin) once every 4 weeks
Study Locations (1 sites)
Mapi pharma Investigational Site ISR001, Tel Aviv, 6423906 Israel
Eligibility Criteria
Inclusion Criteria: 1. Adults aged 18-64 years with T2DM, BMI 25-35 kg/m2 2. On stable Semaglutide 1 mg weekly and for at least 3 months 3. HbA1c \<8%, eGFR≥60 ml/minute 4. For women: either non-childbearing potential or agreement to use acceptable contraception Exclusion Criteria: 1. Participation in another investigational drug clinical study within 3 months 2. History of cardiovascular or cerebrovascular disease 3. Neuropathy or retinopathy or macular edema necessitating medical treatment 4. Type 1 diabetes 5. Unstable weight (\> 5% change in the last 3 months) 6. Current use of insulin and /or sulfonylureas and/or glinides 7. Known contraindications to Semaglutide (per FDA-approved Semaglutide label) 8. Recent immunosuppressive therapy (within 90 days) or chemotherapy for malignancy within 5 years 9. Moderate or severe hepatic impairment, (ALT or AST\> 2 x upper limit of normal (ULN) 10. Severe hypertriglyceridemia (triglycerides \>500 mg/dl) 11. Pregnant or breast feeding 12. Any condition that may increase risk or interfere with study participation (per Investigator judgement)
Conditions Healthy, Obesity
Phase Not Applicable
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with a family history of type 2 diabetes at the University of Missouri. Our aim is to advance understanding of how growth hormone affects beta-cells and risk factors for developing type 2 diabetes.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Beta-cell function (before and 7 days after rhGH administration)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-07-15
Completion: 2030-09-01
Eligibility
Age: 18 Years – 59 Years
Sex: ALL
Volunteers: true
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Missouri-Columbia
Principal Investigators:
  • Bettina Mittendorfer, PhD (PRINCIPAL_INVESTIGATOR) - University of Missouri-Columbia
Contact Information
Study Contact:
Amanda Heider
573-884-6852
ahmc4@health.missouri.edu
Vasavi Shabrish, PhD
v.shabrish@missouri.edu
Bettina Mittendorfer
573-882-9377
b.mittendorfer@missouri.edu
University of Missouri School of Medicine
Interventions
N/A
Study Locations (1 sites)
University of Missouri School of Medicine, Columbia, Missouri 65212 United States
Eligibility Criteria
Inclusion Criteria: * 18 to 59 years old * body mass index ≥30.0 kg/m2 and \<45.0 kg/m2 Additional, group-specific inclusion criteria: * Family history of type 2 diabetes: first degree relative with type 2 diabetes * Control group: no family history of type 2 diabetes Exclusion Criteria: * Pregnant, planning to become pregnant during the study, or breastfeeding * Current diagnosis or history of type 1 or type 2 diabetes * Use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists) * History of bariatric surgery * Known, uncontrolled hypothyroidism * History of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment * Current cancer or cancer that has been in remission less than 5 years * First degree relative with type 1 diabetes diagnosis * Evidence of significant anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease) * Alcohol use disorder, use of controlled substances, or smoking \>2 cigarettes per day * Greater than 3% weight loss within three months of screening or engaged in regular (≥3 days per week), continuous moderate- or high-intensity exercise of ≥30 min duration * Mentally disabled persons, prisoners, and persons with inability to grant voluntary informed consent
Conditions Obesity Type 2 Diabetes Mellitus, Obesit...
Phase Not Applicable
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

This study will examine how eating behaviour changes during the first 18 months of treatment with obesity medications in patients attending the St Vincent's Healthcare Group obesity service. Obesity is increasingly understood as a chronic, relapsing, multifactorial disease that requires long-term management rather than short-term advice alone. Newer anti-obesity medications, particularly glucagon-like peptide-1 receptor agonists and related therapies, have improved weight-loss outcomes and altered the experience of hunger, fullness, food reward, and meal size for many patients. However, while weight reduction is well described in the literature, less is known about how patients themselves experience eating behaviour over time as treatment progresses from initiation to active weight loss and then towards weight maintenance. This study is designed to address that gap by exploring the lived experience of appetite and food-related behaviour across clinically meaningful stages of treatment. The study will use a longitudinal mixed-methods design. Thirty participants aged 16 to 80 years with a body mass index above 27 kg/m2 who are commencing weight-loss medication as part of routine care will be recruited. The sample size includes an allowance for a modest dropout rate over the study period. Participants will be followed at four time points: baseline, approximately 3 months after treatment initiation, around 12 months, and at 18 months, with a visit window of plus or minus 13 days. These time points were selected to reflect distinct phases of treatment. Baseline will capture pre-treatment or very early-treatment experience. Three months is expected to reflect a period of early therapeutic response, when medication effects on appetite may be most noticeable. Twelve months is likely to represent a later phase, when weight loss may be slowing and some patients may be approaching their lowest weight. Eighteen months is intended to capture maintenance or stabilisation, when behavioural changes may differ from those seen earlier in treatment. Data collection will include both questionnaires and semi-structured telephone interviews. The questionnaire component will measure key aspects of eating behaviour, including hunger, fullness, food thoughts, portion size, and palatability. Repeated administration at each study time point will allow changes in these behaviours to be tracked over time. The interview component will provide a richer understanding of how participants describe and interpret their experiences. All interviews will be conducted by one co-investigator using the same core interview guide to ensure consistency. Open-ended questions will allow participants to describe changes in appetite, eating patterns, cravings, meal satisfaction, food preferences, and daily routines in their own words, while additional probing may be used to clarify how these experiences evolve through treatment. Interviews are expected to last 15 to 45 minutes, will be…

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Change in Total Score on the Eating Behavior Patient-Reported Outcomes in Obesity Management Questionnaire (30 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-05-25
Completion: 2026-10-25
Eligibility
Age: 16 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University College Dublin
Contact Information
Study Contact:
Prof Carel W le Roux, MBChB, MSC, FRCP, FRCPath, PhD
353-1-4064781
Carel.leRoux@ucd.ie
Francisca Contreras, MSc
353-1-2214000
Francisca Contreras, MSc, BSc
353-1-2214000
francisca.contreras.h@gmail.com
St Vincent's University Hospital
Interventions
N/A
Study Locations (1 sites)
St Vincent's University Hospital, Dublin, D04 T6F4 Ireland
Eligibility Criteria
Inclusion Criteria: Signed informed consent prior to any study-related procedure Age 16-80 years-old BMI range \> 27 kg/m2 Receiving obesity medication as part of usual care. Exclusion Criteria: * Substance abuse * Pregnancy * Regular use, for more than three times a week for the last 2 months and/or 7 days prior to inclusion, of medications which according to the principal investigator can interfere with the study. * After being included in the study, starting any medication or treatment that could potentially influence the study participation and/or study analysis. * Patients that have had bariatric surgery.
Conditions Sarcopenia, Obesity
Phase Not Applicable
Enrollment 195
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

The study aims to explore whether a high level of AGEs (Advanced Glycation end products) derived from the diet may mediate diet-related muscle loss in Western-type diet, influencing the onset and progression of sarcopenia, predisposing to earlier and more severe metabolic consequences, including type 2 diabetes (T2D). The primary objective of the study is to investigate how the accumulation of AGEs is correlated with muscle loss in adult patients with obesity and type 2 diabetes or lipodystrophy in order to identify possible targets to mitigate the metabolic alterations caused by the Western diet (WD). Specifically, circulating AGEs levels on the skin will be evaluated and correlated with the stage of sarcopenia in a group of patients with obesity and a T2D diagnosis. Furthermore, the relationship between disease duration and AGE levels will be assessed. A secondary objective will be to analyze the clinical data obtained to identify metabolites and metabolic pathways responsible for the phenotype induced by the WD. The ultimate aim of the study is therefore to verify whether high levels of AGEs are correlated with an early and/or more pronounced onset of sarcopenia, concurrently with an increase in inflammation and oxidative stress.

Design

Study type: Observational Observational model: Case Control Time perspective: Cross Sectional

Primary Outcomes

  • Skeletal mass functionality for sarcopenia definition (evaluation of sarcopenia state through study completion, an average of 1 year)
  • Skeletall mass fuctionality for sarcopenia definition (evaluation of sarcopenia state through study completion, an average of 1 year)
  • Skeletall mass calculation for sarcopenia definition (evaluation of sarcopenia state through study completion, an average of 1 year)
  • Number of participants with sarcopenia (evaluation of sarcopenia state through study completion, an average of 1 year)
  • Advanced glycation end products quantification (evaluation of AGEs through study completion, an average of 1 year)
  • Endogenous and exogenous AGEs plasma quantification (evaluation of AGEs through study completion, an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-06-15
Completion: 2027-05-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 195 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Azienda Ospedaliero Universitaria Maggiore della Carita
Principal Investigators:
  • Flavia Prodam, MD PhD (PRINCIPAL_INVESTIGATOR) - AOU Maggiore della Carità di Novara
Contact Information
Study Contact:
Flavia Prodam, MD PhD
+39-0321-660693
flavia.prodam@med.uniupo.it
Flavia Prodam
+39 0321 660 693
flavia.prodam@med.uniupo.it
SCDU Endocrinology, AOU Ospedale Maggiore della Carità
Interventions
N/A
Study Locations (1 sites)
SCDU Endocrinology, AOU Ospedale Maggiore della Carità, Novara, 28100 Italy
Eligibility Criteria
Inclusion Criteria: * Patients of both sexes. * Adults. * BMI compatible with obesity and a diagnosis of type 2 diabetes under good metabolic control (HbA1c \< 7.5%) within 15 years of entry into the study or diagnosis of lipodystrophy (included in the European Consortium of Lipodystrophies (ECLip) Registry (eclip-web.org)) Exclusion Criteria: * Age under 18 years. * Secondary obesity or genetic diseases (Prader-Willi Syndrome, Down Syndrome); metabolic and endocrine disorders (Cushing's syndrome, hypothyroidism). * Subjects with: Inflammatory Bowel Disease (IBD), cancer. * Confirmed or planned pregnancy during the study participation months.